Mayne Pharma launches BAC 300 capsules in the United States. Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of butalbital acetaminophen and caffeine capsule 50mg/300mg/40mg in the United States. Mayne Pharma received approval from the US Food and Drug Administration for its Abbreviated New Drug Application, which is indicated for the treatment of tension headache (migraine).
More:
prnewswire.com/news-releases/mayne-pharma-launches-bac-300-capsules-in-the-united-states-301064172.html
More:
prnewswire.com/news-releases/mayne-pharma-launches-bac-300-capsules-in-the-united-states-301064172.html
No comments:
Post a Comment